Director at Protagonist (NASDAQ: PTGX) trades 9,000 shares under 10b5-1 plan

Rhea-AI Filing Summary

Protagonist Therapeutics director William D. Waddill exercised stock options and sold the resulting shares in a pre-planned transaction. He exercised options for 9,000 shares of common stock at $16.54 per share and sold 9,000 shares at a weighted average price of $117.94 per share. The filing notes these trades were made under a Rule 10b5-1 trading plan adopted on February 27, 2026, indicating they were scheduled in advance. After the transactions, he directly owns 7,825 shares of common stock.

Insights

Equity compensation and insider-trading specialist

Routine 10b5-1 option exercise-and-sell, with common share holdings unchanged.

Director William D. Waddill exercised stock options for 9,000 Protagonist Therapeutics shares at $16.54 and sold 9,000 shares at a weighted average of $117.94. The derivative entry shows the related stock option position falling to zero after exercise.

The filing states the trades occurred under a Rule 10b5-1 plan adopted on February 27, 2026, signaling the timing was pre-scheduled rather than opportunistic. His direct common stock position is 7,825 shares after the transactions, implying the sale primarily monetized option gains while leaving his common share count in place.

Insider Trade Summary 10b5-1

Net Seller: 9,000 shares ($1,061,460)

Net Sell 3 txns

Insider Waddill William D.

Role null

Sold 9,000 shs ($1.06M)

Type	Security	Shares	Price	Value
Exercise	Stock Option (right to buy)	9,000	$0.00	--
Exercise	Common Stock	9,000	$16.54	$149K
Sale	Common Stock	9,000	$117.94	$1.06M

Holdings After Transaction: Stock Option (right to buy) — 0 shares (Direct, null); Common Stock — 16,825 shares (Direct, null)

Footnotes (1)

1. The transactions set forth on this Form 4 were effected pursuant to a 10b5-1 plan adopted by the reporting person on February 27, 2026. The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $117.00 to $119.07. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. These stock options are fully vested.

Key Figures

Shares sold: 9,000 shares Weighted average sale price: $117.94 per share Option exercise price: $16.54 per share +3 more

6 metrics

Shares sold 9,000 shares Common stock sold in open-market transaction on June 23, 2026

Weighted average sale price $117.94 per share Average price for 9,000 common shares sold in multiple trades

Option exercise price $16.54 per share Conversion or exercise price for 9,000 stock options

Shares acquired via exercise 9,000 shares Common stock received from exercising stock options

Shares held after transactions 7,825 shares Director’s direct common stock holdings following Form 4 trades

Remaining derivative position 0 options Stock Option (right to buy) position after 9,000-share exercise

Key Terms

Rule 10b5-1 plan, weighted average sale price, Stock Option (right to buy), derivative exercise/conversion

4 terms

Rule 10b5-1 plan regulatory

"The transactions set forth on this Form 4 were effected pursuant to a 10b5-1 plan adopted by the reporting person"

A Rule 10b5-1 plan is a prearranged, written schedule that lets corporate insiders buy or sell company stock at set times or amounts, even if they later learn material nonpublic information. Think of it like setting an automatic thermostat for trades: it creates a clear record that trades were planned in advance, reducing the risk of insider-trading accusations and helping investors trust that insider transactions are routine rather than based on secret information.

weighted average sale price financial

"The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions"

Stock Option (right to buy) financial

"Stock Option (right to buy) with an expiration date of 2030-05-27 and a conversion or exercise price"

derivative exercise/conversion financial

"transaction_action is derivative exercise/conversion for 9,000 shares underlying common stock"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 06/25/2026 - 04:10 PM Accepted by SEC EDGAR 06/25/2026 - 04:10 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Waddill William D.

(Last) (First) (Middle)

C/O PROTAGONIST THERAPEUTICS, INC.

7707 GATEWAY BLVD., SUITE 140

(Street)

NEWARK CALIFORNIA 94560-1160

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Protagonist Therapeutics, Inc [ PTGX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/23/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/23/2026		M(1)		9,000	A	$16.54	16,825	D
Common Stock	06/23/2026		S		9,000	D	$117.94(2)	7,825	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$16.54	06/23/2026		M			9,000	(3)	05/27/2030	Common Stock	9,000	$0.00	0	D

Explanation of Responses:

1. The transactions set forth on this Form 4 were effected pursuant to a 10b5-1 plan adopted by the reporting person on February 27, 2026.

2. The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $117.00 to $119.07. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

3. These stock options are fully vested.

	/s/ Matthew Gosling, Attorney-in-Fact for William D. Waddill	06/25/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Protagonist Therapeutics (PTGX) director William D. Waddill do in this Form 4?

He exercised stock options for 9,000 Protagonist Therapeutics shares and sold 9,000 shares. The transactions were recorded as an option exercise at $16.54 and an open-market sale at a weighted average price of $117.94 per share.

How many Protagonist Therapeutics (PTGX) shares did the director sell and at what price?

William D. Waddill sold 9,000 shares of Protagonist Therapeutics common stock. The filing reports a weighted average sale price of $117.94 per share, with individual trades executed between $117.00 and $119.07 across multiple transactions.

What stock options did the Protagonist Therapeutics (PTGX) director exercise?

He exercised stock options covering 9,000 shares of Protagonist Therapeutics common stock at a conversion or exercise price of $16.54 per share. A related derivative entry shows the remaining stock option position for these 9,000 shares dropping to zero after the transaction.

How many Protagonist Therapeutics (PTGX) shares does the director hold after these transactions?

Following the reported transactions, William D. Waddill directly owns 7,825 shares of Protagonist Therapeutics common stock. This share count is disclosed as the total common stock beneficially owned directly after the exercise-and-sell activity reported in the filing.

Were the Protagonist Therapeutics (PTGX) insider transactions made under a Rule 10b5-1 plan?

Yes. The filing states the transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 27, 2026. Such plans pre-schedule trades, indicating the timing was arranged in advance rather than chosen opportunistically.

What does the weighted average sale price mean in this Protagonist Therapeutics (PTGX) Form 4?

The weighted average sale price of $117.94 per share reflects multiple trades between $117.00 and $119.07. The filing notes that, upon request, the reporting person will provide full details on the number of shares sold at each separate sale price.